PROTECTING you and your baby

Information for mothers-to-be who have Rh-negative blood

Rhophylac®
Rh(D) Immune Globulin Intravenous (Human)
For Intravenous or Intramuscular injection.
The Rh factor and your baby

Your doctor has identified your blood's Rh factor as Rh negative. This means your red blood cells don't have what is known as the Rh antigen. People who have this antigen are Rh positive. If your baby's father has Rh-positive blood, you might have an Rh-incompatible pregnancy. When your blood is Rh negative and it’s exposed to Rh-positive blood, your body can produce antibodies that attack the Rh-positive blood. This is called “sensitization.” Sensitization is irreversible and can cause serious—but preventable—consequences for your fetus with Rh-positive blood.

Protecting your newborn from HDN

A key concern is that your baby could develop hemolytic disease of the newborn (HDN). This condition can cause liver, spleen, or heart problems. To prevent this risk to your child, and any future children you may have, your doctor may recommend treating you with Rhophylac, an anti-D Rh immune globulin (Rhig). Rhophylac is made by CSL Behring, a company with more than 40 years of experience manufacturing these therapies to prevent serious complications from Rh-incompatible pregnancies.

Important Safety Information

You should not be given Rhophylac if you have had a previous serious allergic reaction to Rhophylac or other human blood products. It should also not be given if your blood has an insufficient quantity of a protein called IgA, has produced antibodies to IgA, and you have known hypersensitivity to IgA. Your physician will do a blood test to assess your situation regarding IgA.

Please see full Important Safety Information on back cover and enclosed full prescribing information for Rhophylac, which includes important safety information for Rhophylac in pregnancy or cases of incompatible transfusion.

How Rh sensitization can affect your pregnancy

Having Rh-negative blood poses no health risk to you. There is also a little risk of it causing complications for your baby during a first pregnancy if you have not been previously Rh sensitized. However, it is possible for a first-time mother who has Rh-negative blood to become sensitized if her blood mixes with Rh-positive blood cells from her baby. This often happens during childbirth, though it can happen earlier in the pregnancy as well. After becoming sensitized, future pregnancies may also be affected.

Protecting your newborn from HDN

A key concern is that your baby could develop hemolytic disease of the newborn (HDN). This condition can cause liver, spleen, or heart problems. To prevent this risk to your child, and any future children you may have, your doctor may recommend treating you with Rhophylac, an anti-D Rh immune globulin (Rhig). Rhophylac is made by CSL Behring, a company with more than 40 years of experience manufacturing these therapies to prevent serious complications from Rh-incompatible pregnancies.

Important Safety Information

You should not be given Rhophylac if you have had a previous serious allergic reaction to Rhophylac or other human blood products. It should also not be given if your blood has an insufficient quantity of a protein called IgA, has produced antibodies to IgA, and you have known hypersensitivity to IgA. Your physician will do a blood test to assess your situation regarding IgA.

Please see full Important Safety Information on back cover and enclosed full prescribing information for Rhophylac, which includes important safety information for Rhophylac in pregnancy or cases of incompatible transfusion.
Rhophylac helps protect your baby

Treatment with Rhophylac can prevent your baby from getting HDN with its risks for liver, spleen, or heart problems. Rhophylac is a sterile human plasma product that helps clear Rh-positive blood from your bloodstream before your body can develop antibodies that could harm your unborn baby.

Your doctor will decide if Rhophylac is right for you

You should not be given Rhophylac if:
• You have had a previous serious allergic reaction to Rhophylac or other human blood products
• You lack a specific protein in your blood, known as IgA, and have had allergic reactions

Important Safety Information

Rhophylac is made from donated human blood. The risk of transmission of infectious agents, including viruses, cannot be completely eliminated. Please see full Important Safety Information on back cover and enclosed full prescribing information for Rhophylac, which includes a boxed warning that does not apply to use of Rhophylac in pregnancy or cases of incompatible transfusion.

How Rhophylac is given

Your doctor will determine how many doses of Rhophylac you will need, as well as when you will receive them, whether during pregnancy or after you deliver. Rhophylac can be given as an injection into a muscle or via an intravenous line into a vein. Your doctor will decide what’s best for you.

Rhophylac following an incomplete pregnancy

Rhophylac may be recommended if you’ve had a miscarriage or abortion. This is because the fetus will likely have started producing red blood cells at about 8 weeks, so sensitization is already possible.

Safety of Rhophylac

Rhophylac is made from human plasma, so the risk that viruses might be transmitted cannot be completely eliminated. However, CSL Behring, the maker of Rhophylac, goes to great lengths to reduce this risk. Rhophylac is produced using plasma exclusively from donors who are screened and healthy. Additionally, the unique manufacturing process for Rhophylac includes several steps that kill and remove viruses that may have been present.

Talk with your doctor about the benefits and risks of taking Rhophylac.
Possible allergic reactions

Many medications, including Rhophylac, can cause allergic reactions in some people. If you experience symptoms such as hives, itchy welts, tightness of the chest, and/or wheezing, tell your doctor immediately. These may be symptoms of hypersensitivity and therefore, Rhophylac should be discontinued. Your doctor will recommend appropriate treatment.

Regarding other medications you might be taking

Tell your doctor about any recent vaccinations you have had, as Rhophylac can lessen their effectiveness. Depending on the type of vaccine, you may need to repeat it later. Your doctor will advise you if this is necessary.

Other side effects that might occur

If you've given Rhophylac as an injection, you may notice some temporary pain or tenderness at the injection site. Regardless of how you are given Rhophylac, you may experience some mild and temporary side effects, such as fever, overall discomfort or uneasiness, headache, hives, welts, and/or chills.

These are just some of the possible side effects, so please tell your doctor about any symptoms you notice, especially ones that don't improve. Be sure to see the full prescribing information for Rhophylac and the Important Safety Information on the back.

Important Safety Information

Immunoglobulin administration can transiently interfere with your response to live virus vaccines, such as measles, mumps and rubella (note that most influenza vaccines are not “live” vaccines). Tell your doctor if you plan to receive a vaccine after receiving Rhophylac.

Please see full Important Safety Information on back cover and enclosed full prescribing information for Rhophylac, which includes a boxed warning that does not apply to use of Rhophylac in pregnancy or cases of incompatible transfusion.

Rhophylac®, Rho(D), Immune Globulin Intravenous (Human), is a blood-derived product. Rhophylac is manufactured by CSL Behring AG and distributed in the U.S. by CSL Behring LLC. Rhophylac is a registered trademark of CSL Behring AG. ©2015 CSL Behring LLC

Please see enclosed full prescribing information for Rhophylac and the Important Safety Information on the back.
Important Safety Information

Rhophylac®, Rh(D), Immune Globulin Intravenous (Human), is a blood-derived injection given to women with an Rh-negative blood type who might have an incompatible pregnancy—that is, might be carrying a child with Rh-positive blood. If a woman in such a pregnancy is not treated, the result could be “isoimmunization,” a condition in which the mother’s Rh-negative blood produces antibodies that could attack the unborn child’s Rh-positive blood cells, potentially causing serious health problems for the unborn child and any future children.

Rhophylac is given by physicians as routine protection against isoimmunization, such as following childbirth. It is also used during pregnancy to prevent complications, increase pregnancy duration, and avoid preterm labor, as well as in incomplete pregnancies. Rhophylac is also used in Rh-negative individuals who have received blood components containing Rh(D) positive red blood cells, for suppression of isoimmunization. Rhophylac can be administered intravenously or intramuscularly, but must not be given to the mother in labor.

You should not be given Rhophylac if you have had a previous serious allergic reaction to Rhophylac or other human blood products. You should not be given Rhophylac if you have had a previous serious allergic reaction to the IgA component of Rhophylac, or if your blood has an insufficient quantity of a protein called IgA, has produced antibodies to IgA, and you have known hypersensitivity to IgA. Your physician will do a blood test to assess your situation regarding IgA.

Some women have experienced mild and temporary reactions after receiving Rhophylac, such as fever, overall discomfort or uneasiness, headache, skin reactions (such as hives or welts); and/or chills. If you received Rhophylac as a shot (intramuscularly), you could experience pain or tenderness at the injection site. If you received Rhophylac as a shot (intramuscularly), you could also experience any reaction or symptom you experience, and see full prescribing information for a more complete list of possible adverse reactions.

Rhophylac is made from donated human blood. The risk of transmission of infectious agents, including viruses, cannot be completely eliminated.

Immunoglobulin administration can transiently interfere with your response to live virus vaccines, such as mumps, measles and rubella (note that most influenza vaccines are not “live” vaccines). Tell your doctor if you plan to receive a vaccine after receiving Rhophylac.

You should not be given Rhophylac if you have had a previous serious allergic reaction to Rhophylac, or other human blood products.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Incompatible transfusions in Rh0(D)-negative individuals transfused with blood
Raising platelet counts in Rh0(D)-positive, non-splenectomized adults with chronic ITP
Immune Thrombocytopenic Purpura (ITP) (1.2)
Suppression of Rhesus (Rh) Isoimmunization (2.2) (IV or IM administration only.)

Warnings and Precautions (5.1.1)           05/2016
Dosage and Administration (2.2)              05/2016
-----------------------------------RECENT MAJOR CHANGES--------------------------------
Rh0(D) Immune Globulin Intravenous (Human) 1500 IU (300 mcg)
RHOPHYLAC.

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use
RHOPHYLAC safely and effectively. See full prescribing information for RHOPHYLAC.

RHOPHYLAC
Rh(D) Immune Globulin Intravenous (Human) 1500 IU (300 mcg)
Solution for Intravenous (IV) or Intramuscular (IM) Injection
Initial US Approval: 2004

WARNING: INTRAVASCULAR HEMOLYSIS IN ITP
See full prescribing information for complete boxed warning. This warning does not apply to Rh(D)-negative patients treated for the
suppression of Rh isoimmunization.

- Intravascular hemolysis leading to death has been reported in Rh(D)-positive patients treated for immune thrombocytopenic purpura (ITP)
  with Rh(D) Immune Globulin Intravenous (Human) products.
- Intravascular hemolysis can lead to clinically compromising anemia and multi-system organ failure including acute respiratory distress
  syndrome (ARDS); acute renal insufficiency, renal failure, and disseminated intravascular coagulation (DIC) have been reported.
- Monitor patients for signs and symptoms of intravascular hemolysis in a healthcare setting for at least 8 hours after administration.

Dosage and Administration (2.2)  05/2016
Warnings and Precautions (5.1.1)  05/2016

INDICATIONS AND USAGE
Rhophylac is an Rh(D) Immune Globulin Intravenous (Human) indicated for:

- Suppression of Rhesus (Rh) Isoimmunization (1.1) in:
  - Pregnancy and obstetric conditions in non-sensitized, Rh(D)-negative women with an Rh-incompatible pregnancy, including:
    - Routine antepartum and postpartum Rh prophylaxis
  - Rh prophylaxis in obstetric complications or invasive procedures
  - Incompatible transfusions in Rh(D)-negative individuals transfused with blood components containing Rh(D)-positive red blood cells (RBCs)

Immune Thrombocytopenic Purpura (ITP) (1.2)
- Raising platelet counts in Rh(D)-positive, non-splenectomized adults with chronic ITP

Adverse Reactions (6.1)
The most common adverse reactions, reported in >14% of subjects, are chills, pyrexia/
dizziness, headache, injection-site pain, and malaise (6.1).

Adverse Reactions (6.1)
The most common adverse reactions, reported in 0.5% of subjects, are nausea,
dizziness, headache, injection-site pain, and malaise (6.1).

DRUG INTERACTIONS

ITP

- Pregnancy: No human or animal data. Use only if clearly needed (8.1).

See 17 for PATIENT COUNSELING INFORMATION.  Revised: May 2016

DRUG INTERACTIONS
7.1 Live Virus Vaccines

USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.3 Nursing Mothers
8.4 Pediatric Use
8.5 Geriatric Use

OVERDOSAGE
10

DESCRIPTION
11

CLINICAL PHARMACOLOGY
12

12.1 Mechanism of Action
12.3 Pharmacokinetics

CLINICAL STUDIES
14

14.1 Suppression of Rh Isoimmunization
14.2 ITP

REFERENCES
15

HOW SUPPLIED/STORAGE AND HANDLING
16

PATIENT COUNSELING INFORMATION
17

* Sections or subsections omitted from the full prescribing information are not listed.
Rhophylac®

Rh0(D) Immune Globulin Intravenous (Human)

**INDICATIONS AND USAGE**

Rhophylac is indicated in Rh0(D)-positive, non-splenectomized adult patients with chronic ITP, as well as Rh0(D)-negative women with an Rh-incompatible pregnancy, including:

- Routine antepartum prophylaxis
- Postpartum prophylaxis (required only if the newborn is Rh(D)-positive)
- Obstetric complications (e.g., miscarriage, abortion, threatened abortion, ectopic pregnancy or hydatidiform mole, transplacental hemorrhage resulting from antepartum hemorrhage)
- Incompatible transfusions
- Invasive procedures during pregnancy (e.g., amniocentesis, chorionic biopsy) or obstetric manipulative procedures (e.g., external version, abdominal trauma)
- Excessive fetomaternal hemorrhage (>15 mL)

**DOSAGE AND ADMINISTRATION**

**Preparation and Handling**

- Rhophylac is a clear or slightly opalescent, colorless to pale yellow solution. Inspect Rhophylac visually for particulate matter and discoloration prior to administration. Do not use if the solution is cloudy or contains particulates.
- Prior to intravenous use, ensure that the needle-free intravenous administration system is compatible with the tip of the Rhophylac glass syringe.
- Do not freeze.
- Bring Rhophylac to room temperature before use.
- Rhophylac is for single use only. Dispose of any unused product or waste material in accordance with local requirements.

**Dosage**

- For treatment of ITP: ADMINISTER RHOPHYLAC BY THE INTRAVENOUS ROUTE ONLY [see Dosage and Administration (2.1)]. Do not administer intramuscularly. A 250 IU (50 mcg) per kg body weight dose of Rhophylac is recommended for patients with ITP. The following formula can be used to calculate the recommended amount of Rhophylac to administer:
  
  \[ \text{Dose (IU)} = \frac{\text{Total IU}}{1500 \text{ IU per syringe}} \times \text{Number of syringes} \]

- Rhophylac should be administered by intravenous or intramuscular injection. If large doses (greater than 5 mL) are required and intramuscular injection is chosen, it is advisable to administer Rhophylac in divided doses at different sites.

- Ensure the site of administration will allow the injection to reach the muscle if Rhophylac is administered intramuscularly. Consider intravenous administration if reaching the muscle is of concern [see Adverse Reactions (6.2)]. Do not administer Rhophylac subcutaneously into the fatty tissue.

**Contraindications**

- Rhophylac is contraindicated in IgA-deficient patients with antibodies to IgA and a history of hypersensitivity to Rhophylac or any of its components.
- Do not administer Rhophylac to the newborn infant of a mother that received Rhophylac postpartum.

**Table 1: Dosing Guidelines for Suppression of Rh Isoimmunization**

<table>
<thead>
<tr>
<th>Indication</th>
<th>Timing of Administration</th>
<th>Dose* (Administer by Intravenous or Intramuscular Injection)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rh-incompatible pregnancy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Routine antepartum prophylaxis</td>
<td>At Week 28-30 of gestation</td>
<td>1500 IU (300 mcg)</td>
</tr>
<tr>
<td>Postpartum prophylaxis</td>
<td>Within 72 hours of birth</td>
<td>1500 IU (300 mcg)</td>
</tr>
<tr>
<td>Obstetric complications</td>
<td>Within 72 hours of complication</td>
<td>1500 IU (300 mcg)</td>
</tr>
<tr>
<td>Incompatible transfusions</td>
<td>Within 72 hours of procedure</td>
<td>1500 IU (300 mcg)</td>
</tr>
<tr>
<td>Excessive fetomaternal hemorrhage (&gt;15 mL)</td>
<td>Within 72 hours of complication</td>
<td>1500 IU (300 mcg)</td>
</tr>
</tbody>
</table>

**Dosage Forms and Strengths**

1500 IU (300 mcg) per 2 mL prefilled, ready-to-use, glass syringe for IV or IM use.

**Full Prescribing Information**

CSL Behring
5 WARNINGS AND PRECAUTIONS

5.1 Both Indications

5.1.1 Hypersensitivity

Severe hypersensitivity reactions may occur even in patients who have tolerated previous administrations. If symptoms of allergic or early signs of hypersensitivity reactions (including generalized urticaria, tightness of the chest, wheezing, hypotension, and anaphylaxis) occur, discontinue Rhophylac administration immediately and institute appropriate treatment. Medications such as epinephrine should be available for immediate treatment of acute hypersensitivity reactions to Rhophylac or any of its components.

Rhophylac contains trace amounts of IgA (less than 5 mcg/mL) [see Description (11)]. Patients with known antibodies to IgA have a risk of developing potentially severe hypersensitivity and anaphylactic reactions. Rhophylac is contraindicated in patients with antibodies against IgA and a history of hypersensitivity reactions [see Contraindications (4)].

5.1.2 Interference with Laboratory Tests

The administration of Rh(D) immune globulin may affect the results of blood typing, the antibody screening test, and the direct antiglobulin (Coombs') test. Antepartum administration of Rh(D) immune globulin to the mother can also affect these tests in the newborn infant.

Rhophylac can contain antibodies to other Rh antigens (e.g., anti-C antibodies), which might be detected by sensitive serological tests following administration.

5.1.3 Transmissible Infectious Agents

Because Rhophylac is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk of infectious agent transmission has been reduced by screening plasma donors for prior exposure to certain viruses, testing for the presence of certain current infectious agents, and including virus inactivation/removal steps in the manufacturing process for Rhophylac.

Any infections thought to be possibly transmitted by Rhophylac to CSL Behring Pharmacovigilance at 1-866-915-6958.

5.2 ITP

5.2.1 Intravascular Hemolysis

Serious intravascular hemolysis has occurred in a clinical study with Rhophylac. All cases resolved completely. However, as reported in the literature, some Rh(D)-positive patients treated with Rh(D) Immune Globulin Intravenous (Human) for ITP developed clinically compromising anemia, acute renal insufficiency, and, very rarely, disseminated intravascular coagulation (DIC) and death.2 Note: This warning does not apply to Rh(D)-negative patients treated for the suppression of Rh isoimmunization.

Monitor patients in a healthcare setting for at least 8 hours after administration of Rhophylac. Perform a dipstick urinalysis at baseline, 2 hours and 4 hours after administration, and prior to the end of the monitoring period.

Alert patients to, and monitor them for, the signs and symptoms of intravascular hemolysis, including back pain, shaking chills, fever, and discolored urine or hematuria. Absence of these signs and/or symptoms of intravascular hemolysis within 8 hours do not indicate intravascular hemolysis cannot occur subsequently.

If signs and/or symptoms of intravascular hemolysis are present or suspected after Rhophylac administration, perform post-treatment laboratory tests, including plasma hemoglobin, lactate dehydrogenase (LDH), and plasma bilirubin (direct and indirect). DIC may be difficult to detect in the ITP population; the diagnosis is dependent mainly on laboratory testing.

If patients who develop hemolysis with clinically compromising anemia after receiving Rhophylac are to be transfused, Rh(D)-negative packed RBCs should be used to avoid exacerbating ongoing hemolysis.

5.2.2 Pre-existing Anemia

The safety of Rhophylac in the treatment of ITP has not been established in patients with pre-existing anemia. Rhophylac may increase the severity of anemia.

6 ADVERSE REACTIONS

The most serious adverse reactions in patients receiving Rh(D) Immune Globulin Intravenous (Human) have been observed in the treatment of ITP and include intravascular hemolysis, clinically compromising anemia, acute renal insufficiency, and, very rarely, DIC and death [see Boxed Warning, and Warnings and Precautions (5.3.1)].2 The most common adverse reactions observed in the use of Rhophylac for suppression of Rh isoimmunization (≥0.5% of subjects) are nausea, dizziness, headache, injection-site pain, and malaise.

The most common adverse reactions observed in the treatment of ITP (>14% of subjects) are chills, pyrexia/increased body temperature, and headache. Hemolysis (manifested by an increase in bilirubin, a decrease in hemoglobin, or a decrease in haptoglobin) was also observed.

6.1 Clinical Studies Experience

Because clinical studies are conducted under different protocols and widely varying conditions, adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in practice.

6.2 Postmarketing Experience

Because postmarketing adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to product exposure. The following adverse reactions have been identified during post-approval use of Rhophylac:

Suppression of Rh Isoimmunization

Hypersensitivity reactions, including rare cases of anaphylactic shock or anaphylactoid reactions, headache, dizziness, vertigo, hypotension, tachycardia, dyspnea, nausea, vomiting, rash, urticaria, pruritus, chills, pyrexia, malaise, diarrhea and back pain have been reported. Transient injection-site irritation and pain have been observed following intramuscular administration.

There have been reports of lack of effect in patients with a body mass index ≥30 when administration via the intramuscular route was attempted [see Dosing and Administration (2.2)].

ITP

Transient hemoglobinuria has been reported in a patient being treated with Rhophylac for ITP.

7 DRUG INTERACTIONS

7.1 Live Virus Vaccines

Passive transfer of antibodies may transiently impair the immune response to live attenuated virus vaccines such as measles, mumps, rubella, and varicella [see Patient Counseling Information (17)]. Do not immunize with live vaccines within 3 months after the final dose of Rhophylac. If Rhophylac is administered within 14 days after administration of a live vaccine, the immune response to the vaccination may be inhibited.2

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C. Animal reproduction studies have not been conducted with Rhophylac.

Suppression of Rh Isoimmunization

Rhophylac is used in pregnant women for the suppression of Rh isoimmunization. The available evidence suggests that Rhophylac does not harm the fetus or affect future
pregnancies or reproduction capacity when given to pregnant Rh(D)-negative women for suppression of Rh isoimmunization.\(^4\)

ITP

Rhophylac has not been evaluated in pregnant women with ITP.

8.3 Nursing Mothers

Suppression of Rh Isoimmunization

Rhophylac is used in nursing mothers for the suppression of Rh isoimmunization. No undesirable effects on a nursing infant are expected during breastfeeding.

ITP

Rhophylac has not been evaluated in nursing mothers with ITP.

8.4 Pediatric Use

Suppression of Rh Isoimmunization in Incompatible Transfusions

The safety and effectiveness of Rhophylac have not been established in pediatric subjects being treated for an incompatible transfusion. The physician should weigh the potential risks against the benefits of Rhophylac, particularly in girls whose later pregnancies may be affected if Rh isoimmunization occurs.

Chronic ITP

The safety and effectiveness of Rhophylac have not been established in pediatric subjects with chronic ITP. Dosing in the treatment of children with chronic ITP is expected to be similar to adults.

8.5 Geriatric Use

Suppression of Rh Isoimmunization in Incompatible Transfusions

Rhophylac has not been evaluated for treating incompatible transfusions in subjects 65 years of age and older.

ITP

Of the 98 subjects evaluated in the clinical study of Rhophylac for treatment of ITP (see Clinical Studies (14.2)), 19% were 65 years of age and older. No overall differences in effectiveness or safety were observed between these subjects and younger subjects.

10 OVERDOSAGE

There are no reports of known overdoses in patients being treated for suppression of Rh isoimmunization or ITP. Patients with incompatible transfusion or ITP who receive an overdose of Rh(D) immune globulin should be monitored because of the potential risk for hemolysis.

11 DESCRIPTION

Rhophylac is a sterile Rh(D) Immune Globulin Intravenous (Human) (anti-D) solution in a ready-to-use prefilled glass syringe for intravenous or intramuscular injection. One syringe contains at least 1500 IU (300 mcg) of IgG antibodies to Rh0(D) in a 2 mL solution, in a ready-to-use prefilled glass syringe for intravenous or intramuscular injection. No undesirable effects on a nursing infant are expected during breastfeeding.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Suppression of Rh Isoimmunization

The mechanism by which Rh(D) immune globulin suppresses immunization to Rh(D)-positive RBCs is not completely known.

In a clinical study of Rh(D)-negative healthy male volunteers, both the intravenous and intramuscular administration of a 1500 IU (300 mcg) dose of Rhophylac 24 hours after injection of 15 mL of Rh(D)-positive RBCs resulted in an effective clearance of Rh(D)-positive RBCs. On average, 99% of injected RBCs were cleared within 12 hours following intravenous administration and within 144 hours following intramuscular administration.

ITP

Rhophylac has been shown to increase platelet counts and to reduce bleeding in non-splenectomized Rh(D)-positive subjects with chronic ITP. The mechanism of action is thought to involve the formation of Rh(D) immune globulin RBC complexes, which are preferentially removed by the reticuloendothelial system, particularly the spleen. This results in Fc receptor blockade, thus sparing antibody-coated platelets.\(^a\)

12.3 Pharmacokinetics

Suppression of Rh Isoimmunization

In a clinical study comparing the pharmacokinetics of intravenous versus intramuscular administration, 15 Rh(D)-negative pregnant women received a single 1500 IU (300 mcg) dose of Rhophylac at Week 28 of gestation.\(^9\)

Following intravenous administration, peak serum levels of Rh(D) immune globulin ranged from 62 to 84 ng/mL after 1 day (i.e., the time the first blood sample was taken following the antepartum dose). Mean systemic clearance was 0.20 ± 0.03 ml/min, and half-life was 16 ± 4 days.

Following intramuscular administration, peak serum levels ranged from 7 to 46 ng/mL and were achieved between 2 and 7 days. Mean apparent clearance was 0.29 ± 0.12 ml/min, and half-life was 18 ± 5 days. The absolute bioavailability of Rhophylac was 69%.

Regardless of the route of administration, Rh(D) immune globulin titers were detected in all women up to at least 9 weeks following administration of Rhophylac.

ITP

Pharmacokinetic studies with Rhophylac were not performed in Rh(D)-positive subjects with ITP. Rh(D) immune globulin binds rapidly to Rh(D)-positive erythrocytes.\(^1\)

14 CLINICAL STUDIES

14.1 Suppression of Rh Isoimmunization

In two clinical studies, 447 Rh(D)-negative pregnant women received a 1500 IU (300 mcg) dose of Rhophylac during Week 28 of gestation. The women who gave birth to an Rh(D)-positive baby received a second 1500 IU (300 mcg) dose within 72 hours of birth.

• Study 1 (Pharmacokinetic Study) – Eight of the women who participated in the pharmacokinetic study [see Clinical Pharmacology (12.3)] gave birth to an Rh(D)-positive baby and received the postpartum dose of 1500 IU (300 mcg) of Rhophylac.\(^9\) Antibody tests performed 6 to 8 months later were negative for all women. This suggests that no Rh(D) immunization occurred.

• Study 2 (Pivotal Study) – In an open-label, single-arm clinical study at 22 centers in the US and United Kingdom, 432 pregnant women received the antepartum dose of 1500 IU (300 mcg) of Rhophylac either as an intravenous or intramuscular injection (two randomized groups of 216 women each).\(^1\) Subjects received an additional 1500 IU (300 mcg) dose if an obstetric complication occurred between the routine antepartum dose and birth or if extensive fetomaternal hemorrhage was measured after birth. Of the 270 women who gave birth to an Rh(D)-positive baby, 248 women were evaluated for Rh(D) immunization 6 to 11.5 months postpartum. None of these women developed antibodies against the Rh(D) antigen.

14.2 ITP

In an open-label, single-arm, multicenter study, 98 Rh(D)-positive adult subjects with chronic ITP and a platelet count of 30 x 10^9/L or less were treated with Rhophylac. Subjects received a single intravenous dose of 250 IU (50 mcg) per kg body weight. The primary efficacy endpoint was the response rate defined as achieving a platelet count of ≥30 x 10^9/L as well as an increase of >20 x 10^9/L within 15 days after treatment with Rhophylac. Secondary efficacy endpoints included the response rate defined as an increase in platelet counts to ≥50 x 10^9/L within 15 days after treatment and, in subjects who had bleeding at baseline, the regression of hemorrhage defined as any decrease from baseline in the severity of overall bleeding status. Table 4 presents the primary response rates for the intent-to-treat (ITT) and per-protocol (PP) populations.

Table 3: Virus Inactivation and Removal in Rhophylac

<table>
<thead>
<tr>
<th>Virus property</th>
<th>HIV</th>
<th>PRV</th>
<th>BVDV</th>
<th>MVM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genome</td>
<td>RNA</td>
<td>DNA</td>
<td>RNA</td>
<td>DNA</td>
</tr>
<tr>
<td>Envelope</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Size (nm)</td>
<td>80-100</td>
<td>120-200</td>
<td>40-70</td>
<td>18-24</td>
</tr>
<tr>
<td>Manufacturing step</td>
<td>Mean LRF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Solvent/detergent treatment</td>
<td>≥6.0</td>
<td>≥5.6</td>
<td>≥5.4</td>
<td>Not tested</td>
</tr>
<tr>
<td>Chromatographic process steps</td>
<td>4.5</td>
<td>≥3.9</td>
<td>1.6</td>
<td>≥2.6</td>
</tr>
<tr>
<td>Virus filtration</td>
<td>≥6.3</td>
<td>≥5.6</td>
<td>≥5.5</td>
<td>3.4</td>
</tr>
<tr>
<td>Overall reduction (log10 units)</td>
<td>≥16.8</td>
<td>≥15.1</td>
<td>≥12.5</td>
<td>≥6.0</td>
</tr>
</tbody>
</table>

HIV, a model for HIV-1 and HIV-2; PRV, pseudorabies virus, a model for large, enveloped DNA viruses (e.g., herpesvirus); BVDV, bovine viral diarrhea virus, a model for HIV and West Nile virus; MVM, minute virus of mice, a model for B19V and other small, non-enveloped DNA viruses.
Table 4: Primary Response Rates (ITT and PP Populations)

<table>
<thead>
<tr>
<th>Analysis Population</th>
<th>No. Subjects</th>
<th>No. Responders</th>
<th>Primary Response Rate at Day 15</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>% Responders</td>
</tr>
<tr>
<td>ITT</td>
<td>98</td>
<td>65</td>
<td>66.3%</td>
</tr>
<tr>
<td>PP</td>
<td>92</td>
<td>62</td>
<td>67.4%</td>
</tr>
</tbody>
</table>

The primary efficacy response rate (ITT population) demonstrated a clinically relevant response to treatment, i.e., the lower bound of the 95% confidence interval (CI) was greater than the predefined response rate of 50%. The median time to platelet response was 3 days, and the median duration of platelet response was 22 days.

Table 5: Response Rates By Baseline Platelet Count (ITT Population)

<table>
<thead>
<tr>
<th>Baseline Platelet Count (x 10^9/L)</th>
<th>Total No. Subjects</th>
<th>No. (%) Subjects Achieving a Platelet Count of ≥30 x 10^9/L and an Increase of &gt;20 x 10^9/L</th>
<th>No. (%) Subjects With an Increase in Platelet Counts to ≥50 x 10^9/L</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤10</td>
<td>38</td>
<td>15 (39.5)</td>
<td>10 (26.3)</td>
</tr>
<tr>
<td>&gt;10 to 20</td>
<td>28</td>
<td>22 (78.6)</td>
<td>17 (60.7)</td>
</tr>
<tr>
<td>&gt;20 to 30</td>
<td>27</td>
<td>24 (88.9)</td>
<td>22 (81.5)</td>
</tr>
<tr>
<td>&gt;30*</td>
<td>5</td>
<td>4 (80.0)</td>
<td>5 (100.0)</td>
</tr>
<tr>
<td>Overall (all subjects)</td>
<td>98</td>
<td>65 (66.3)</td>
<td>54 (55.1)</td>
</tr>
</tbody>
</table>

* Reflects subjects with a platelet count of ≤30 x 10^9/L at screening but >30 x 10^9/L immediately before treatment.

During the study, an overall regression of hemorrhage was seen in 44 (88%, 95% CI: 76% to 94%) of the 50 subjects with bleeding at baseline. The percentage of subjects showing a regression of hemorrhage increased from 20% at Day 2 to 64% at Day 15. There was no evidence of an association between the overall hemorrhage regression rate and baseline platelet count. Approximately half of the 98 subjects in the ITT population had evidence of bleeding at baseline. Post-baseline, the percentage of subjects without bleeding increased to a maximum of 70.4% at Day 8.

15 REFERENCES


16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

- Rhophylac 1500 IU (300 mcg) is supplied in packages of one or ten (10) prefilled, ready-to-use, glass syringes, each containing 2 mL liquid for injection. Each syringe is accompanied by a SafetyGlide™ needle for intravenous or intramuscular use.

Each product presentation includes a package insert and the following components:

<table>
<thead>
<tr>
<th>Presentation</th>
<th>Carton NDC Number</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>1500 IU (300 mcg) Multipack</td>
<td>44206-300-10</td>
<td>Ten single-use, prefilled 2 mL syringes [NDC 44206-300-90]</td>
</tr>
<tr>
<td>1500 IU (300 mcg) Multipack</td>
<td>44206-300-90</td>
<td>Ten SafetyGlide needles</td>
</tr>
</tbody>
</table>

16.2 Storage and Handling

- DO NOT FREEZE.
- Rhophylac contains no preservatives; do not store at room temperature.
- Store at 2 to 8°C (36 to 46°F) for a shelf life of 36 months from the date of manufacture, as indicated by the expiration date printed on the outer carton and syringe label.
- Keep Rhophylac in its original carton to protect it from light.
- The prefilled Rhophylac syringe is not made with natural rubber latex.

17 PATIENT COUNSELING INFORMATION

Both Indications

- Inform patients to immediately report the following signs and symptoms to their physician: hives, chest tightness, wheezing, hypotension, and anaphylaxis [see Warnings and Precautions (5.1)].
- Inform patients that Rhophylac is made from human blood and may contain infectious agents that can cause disease (e.g., viruses and, theoretically, the CJD agent). Explain that the risk Rhophylac may transmit an infectious agent has been reduced by screening all plasma donors, by testing the donated plasma for certain viruses, and by inactivating and/or removing certain viruses during manufacturing. Advise patients to report any symptoms that concern them and that may be related to viral infections [see Warnings and Precautions (5.1.1)].
- Inform patients that Rhophylac may interfere with the response to live virus vaccines (e.g., measles, mumps, rubella, and varicella), and instruct them to notify their healthcare professional of this potential interaction when they are receiving vaccinations.

Suppression of Rh Isoimmunization

- Inform patients receiving the antepartum dose of Rhophylac for suppression of Rh isoimmunization that they will need a second dose within 72 hours of birth if the baby’s blood type is Rh-positive.

ITP

- Instruct patients being treated with Rhophylac for ITP to immediately report symptoms of intravascular hemolysis, including back pain, shakiness, fever, discolored urine, decreased urine output, sudden weight gain, edema, and/or shortness of breath [see Warnings and Precautions (5.2.1)].

Manufactured by:

CSL Behring AG
Bern, Switzerland
US License No. 1766

Distributed by:

CSL Behring LLC
Kankakee, IL 60901 USA

Triton™ is a trademark of The Dow Chemical Company
Planova® is a registered trademark of Asahi Kasei Medical Co., Ltd.
SafetyGlide™ is a trademark of Becton, Dickinson and Company